Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
Authors
Keywords
CD40L, 5-Fluorouracil, Immunotherapy, Chemotherapy, Urinary bladder cancer
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 3, Pages 273-282
Publisher
Springer Nature
Online
2013-12-19
DOI
10.1007/s00262-013-1507-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
- (2013) Rupal Ramakrishnan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
- (2012) I. Diaconu et al. CANCER RESEARCH
- Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
- (2012) S. Pesonen et al. CANCER RESEARCH
- Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses
- (2011) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
- (2011) Dalil Hannani et al. CANCER JOURNAL
- The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas
- (2011) Pauline G. Knox et al. JOURNAL OF CELL BIOLOGY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial
- (2010) P.-U. Malmstrom et al. CLINICAL CANCER RESEARCH
- Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas
- (2009) L Vardouli et al. CANCER GENE THERAPY
- Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells
- (2009) E. M. Gomes et al. CLINICAL CANCER RESEARCH
- Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
- (2009) Luigi Dolcetti et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- The Janus faces of CD40 in cancer
- (2009) Angelica S.I. Loskog et al. SEMINARS IN IMMUNOLOGY
- CD40 Induces Antigen Transporter and Immunoproteasome Gene Expression in Carcinomas via the Coordinated Action of NF- B and of NF- B-Mediated De Novo Synthesis of IRF-1
- (2008) A. Moschonas et al. MOLECULAR AND CELLULAR BIOLOGY
- How tumours escape mass destruction
- (2008) T J Stewart et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started